Brightening Cream and Lasers in Post-sclerotherapy Hyperpigmentation

Last updated: March 18, 2025
Sponsor: Insel Gruppe AG, University Hospital Bern
Overall Status: Completed

Phase

N/A

Condition

Varicose Veins

Treatment

Triple cream

QS Nd:YAG laser

Clinical Study ID

NCT05165524
2021-D0062
  • Ages > 18
  • All Genders

Study Summary

The treatment of leg veins and varicosis with sclerotherapy is one of the most frequently performed medical intervention in the western world. The most common local side effects of this treatment are hyperpigmentations caused by hemosiderin deposition in the skin as well as post inflammatory hyperpigmentation.

Although skin hyperpigmentation after sclerotherapy is a common over several months up to years lasting side-effect with a strong aesthetic impact, scanty data exist about treatment options.

Quality-Switched (QS) lasers are efficient in the removal of exogenous and endogenous pigments, such as tattoos as well as epidermal and dermal melanin deposits. The laser light is absorbed by pigment particles, leading to a fragmentation of these particles by a photothermal and photoacoustic effect. Smaller particles can be then phagocyted by macrophages, and transported via the lymphatic system into the lymph nodes. Furthermore, the positive effect of QS lasers in the management of cutaneous siderosis in stasis dermatitis and after sclerotherapy has been described in several cases.

Triple cream including hydroquinone, tretinoin and a topical corticosteroid (eg dexamethasone), is the first line therapy in the treatment of post inflammatory hyperpigmentation.

This randomized controlled study aims to evaluate the efficiency of two well-known depigmentation methods (QS laser and triple cream) for treatment of post sclerotherapy hyperpigmentation, compared with a control group performing no treatment.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Fitzpatrick skin type I-IV

  • Presence of at least 1 postinflammatory hyperpigmentation after sclerotherapy

Exclusion

Exclusion Criteria:

  • History of adverse events related to short-pulsed laser therapy

  • Pregnant or breast-feeding women

  • Intention to become pregnant during the course of the study

  • History of intolerance or allergic reaction to triple cream or one of itsingredients

  • Prior treatment with parenteral gold therapy

  • Inability to understand the study content

Study Design

Total Participants: 66
Treatment Group(s): 2
Primary Treatment: Triple cream
Phase:
Study Start date:
March 03, 2022
Estimated Completion Date:
January 14, 2025

Connect with a study center

  • Department of dermatology, University Hospital Inselspital, Bern

    Bern, 3010
    Switzerland

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.